These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32727149)

  • 41. Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.
    Ichihara K; Masumori N; Iwasawa A; Taguchi K; Yamaguchi Y; Nishimura M; Sasamura H; Suzuki N; Haga K; Miyao N; Hirose T
    Int J Urol; 2018 Oct; 25(10):849-854. PubMed ID: 30066966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
    Komiya A; Suzuki H; Awa Y; Egoshi K; Onishi T; Nakatsu H; Ohki T; Mikami K; Sato N; Araki K; Ota S; Naya Y; Ichikawa T
    Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction].
    Yamanaka N; Yamaguchi O; Kameoka H; Fukaya Y; Yokota T; Shiraiwa Y; Yokoyama J; Kumakawa K; Itou K; Kuma Y
    Hinyokika Kiyo; 1991 Dec; 37(12):1759-72. PubMed ID: 1723843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.
    Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
    Radiat Oncol; 2014 Dec; 9():302. PubMed ID: 25544509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin].
    Furuya R; Hisasue S; Ogura H; Furuya S; Masumori N; Itoh N; Tsukamoto T
    Hinyokika Kiyo; 2005 Nov; 51(11):763-6. PubMed ID: 16363711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Naftopidil is useful for the treatment of malignant pleural mesothelioma.
    Mikami K; Nagaya H; Gotoh A; Kanno T; Tsuchiya A; Nakano T; Nishizaki T
    Pharmacology; 2014; 94(3-4):163-9. PubMed ID: 25301502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.
    Batty M; Pugh R; Rathinam I; Simmonds J; Walker E; Forbes A; Anoopkumar-Dukie S; McDermott CM; Spencer B; Christie D; Chess-Williams R
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27537875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study.
    Kwon SY; Lee KS; Yoo TK; Chung JI; Lee JY; Hong JH; Seo SI; Jung TY; Kwak C; Kang TW; Yun SJ
    Urology; 2018 Jan; 111():145-150. PubMed ID: 28624553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
    Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of silodosin, tamsulosin, and naftopidil with delirium: analysis of the pharmacovigilance database in Japan.
    Kotake K; Noritake Y; Kawakami Y
    Int J Clin Pharm; 2023 Oct; 45(5):1252-1259. PubMed ID: 37713027
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].
    Kawabe K
    Yakugaku Zasshi; 2006 Mar; 126 Spec no.():199-206. PubMed ID: 16518083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists.
    Björnebo L; Razdan S; Discacciati A; Palsdottir T; Aly M; Nordström T; Eklund M; Lundon D; Grönberg H; Tewari A; Wiklund P; Kyprianou N; Lantz A
    J Natl Cancer Inst; 2024 Sep; 116(9):1459-1465. PubMed ID: 38718219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
    Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re: Long-Term Treatment and Prognostic Factors of alpha1-Blockers for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Pilot Study Comparing Naftopidil and Tamsulosin Hydrochloride.
    Kaplan SA
    J Urol; 2011 Jan; 185(1):227. PubMed ID: 22082931
    [No Abstract]   [Full Text] [Related]  

  • 56. Editorial comment from Dr Funahashi to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
    Funahashi Y
    Int J Urol; 2013 May; 20(5):521. PubMed ID: 23131001
    [No Abstract]   [Full Text] [Related]  

  • 57. Editorial comment from Dr Ishizuka to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
    Ishizuka O
    Int J Urol; 2013 May; 20(5):520. PubMed ID: 23078593
    [No Abstract]   [Full Text] [Related]  

  • 58. Editorial comment from Dr Park to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
    Park WH
    Int J Urol; 2013 May; 20(5):519-20. PubMed ID: 23078577
    [No Abstract]   [Full Text] [Related]  

  • 59. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
    Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
    Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.